Vascular News and Research

RSS

NCI funds new Center on Microenvironment and Metastasis to research on cancer

Adding potent research firepower and fresh physical perspectives to combat cancer, the National Cancer Institute (NCI) has funded the new Center on the Microenvironment and Metastasis, which will be headquartered at Cornell University.

27 Oct 2009

National Cancer Institute awards Johns Hopkins $14.8 million for cancer research

Researchers from the Johns Hopkins Institute for NanoBioTechnology have been awarded $14.8 million from the National Cancer Institute to launch a research center aimed at unraveling the physical underpinnings of the growth and spread of cancer.

26 Oct 2009

Cardio Vascular Medical Device releases shareholders update

Cardio Vascular Medical Device Corp., a leading developer of advanced cardiovascular surgery technology, today released a brief shareholders update.

26 Oct 2009

Vision loss after non-ocular surgery is rare but potentially devastating

Vision loss after non-ocular surgery is a rare but potentially devastating surgical complication that is usually the result of cortical blindness, ischemic optic neuropathy or retinal vascular occlusion. Due to its rare and unexpected occurrence, the origin of perioperative vision loss (POVL) is poorly understood.

26 Oct 2009

Obese patients less likely to achieve cholesterol and blood pressure control

Obese patients taking medications to lower their blood pressure and cholesterol levels are less likely to reach recommended targets for these cardiovascular disease risk factors than their normal weight counterparts, according to new research presented at the 2009 Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society and the Heart and Stroke Foundation of Canada.

26 Oct 2009

APC enzyme may be effective for treating amyotrophic lateral sclerosis

A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years.

26 Oct 2009

Pulmo BioTech signs agreement with Biotechnology Consulting Poland for commercialization of PulmoBind

Pulmo BioTech Inc. has announced that it will ultimately receive at least $3.3 million pursuant to the license agreement contemplated by the previously announced non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. with respect to its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development work, clinical trials and ultimately, commercialization in the European market.

24 Oct 2009

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand treatment capabilities and bring new hope for patients presenting serious conditions.

From Elekta 24 Oct 2009

University neurologists launch multiple sclerosis research study

Neurologists at the University at Buffalo are beginning a research study that could overturn the prevailing wisdom on the cause of multiple sclerosis (MS).

24 Oct 2009

Clinical results of FlexStent Femoropopliteal Self Expanding Stent System presented

Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.

24 Oct 2009

Sickle cell disease can be treated with resveratrol extract, according to researchers

An extract in red grape skin may be a new treatment for sickle cell disease, Medical College of Georgia researchers say.

23 Oct 2009

Vasamed partners with BBHOP for peripheral arterial disease research

On Saturday, November 7, 2009 Vasamed Inc., provider of diagnostic technologies that detect peripheral arterial disease in patients with diabetes, will partner with the Black Barbershop Health Outreach Program (BBHOP) in its mission to help African Americans identify the connection between peripheral arterial disease (PAD), diabetes, obesity and hypertension through early detection and referral to appropriate medical resources.

23 Oct 2009

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that it has signed a long-term multi-project research and license collaboration agreement with Roche.

23 Oct 2009

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.

22 Oct 2009

Peripheral arterial disease linked to lifestyle changes

Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. And while PAD can progress and worsen over time, there is not enough evidence yet to advocate minimally invasive treatment in patients who have had a narrowing or blockage of a leg artery but showing no signs or symptoms of the disease, say Irish researchers in a retrospective study of more than 900 individuals.

22 Oct 2009

Edwards Lifesciences announces third quarter 2009 results

Edwards Lifesciences Corporation, a world leader in products and technologies to treat advanced cardiovascular disease, today reported net income for the quarter ended September 30, 2009 of $73.5 million, or $1.25 per diluted share, compared to net income of $32.9 million, or $0.56 per diluted share, for the same period in 2008.

22 Oct 2009

New findings from ADVANCE clinical trial presented

New analyses of the largest-ever clinical trial of patients with type 2 diabetes show that the combination of blood pressure lowering treatment and intensive glucose (blood sugar) control improved patients' vascular condition and resulted in a significant 18 percent reduction in the risk of death from all causes.

22 Oct 2009

Eyes may mirror Alzheimer's disease

The eyes may be the windows to the soul, but new research indicates they also may mirror a brain ravaged by Alzheimer's disease.

22 Oct 2009

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.

21 Oct 2009

Raydiance makes major breakthrough by manufacturing bioabsorbable vascular stent materials

Raydiance Corporation, developer of the world’s first commercial-grade ultrafast laser, announced today that it has made a major breakthrough in manufacturing a wide variety of bio-absorbable materials with precise, micron-resolution feature sizes and with no heat affected zones (HAZ).

21 Oct 2009

Vascular News and Research

NCI funds new Center on Microenvironment and Metastasis to research on cancer

National Cancer Institute awards Johns Hopkins $14.8 million for cancer research

Cardio Vascular Medical Device releases shareholders update

Vision loss after non-ocular surgery is rare but potentially devastating

Obese patients less likely to achieve cholesterol and blood pressure control

APC enzyme may be effective for treating amyotrophic lateral sclerosis

Pulmo BioTech signs agreement with Biotechnology Consulting Poland for commercialization of PulmoBind

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

University neurologists launch multiple sclerosis research study

Clinical results of FlexStent Femoropopliteal Self Expanding Stent System presented

Sickle cell disease can be treated with resveratrol extract, according to researchers

Vasamed partners with BBHOP for peripheral arterial disease research

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

Peripheral arterial disease linked to lifestyle changes

Edwards Lifesciences announces third quarter 2009 results

New findings from ADVANCE clinical trial presented

Eyes may mirror Alzheimer's disease

New results from ADVANCE provide important insights to reduce diabetes complications

Raydiance makes major breakthrough by manufacturing bioabsorbable vascular stent materials

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News